Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.

Congenital heart disease entails increased odds of autism spectrum disorder

10 Nov 2019

Children with congenital heart disease (CHD) are at increased risk of developing autism spectrum disorder (ASD), particularly those with atrial or ventricular septal defect, a recent study suggests.

Researchers conducted a case-control study of 8,760 children with ASD and 26,280 non-ASD controls using data from the US Military Health System. The two groups were similar in terms of characteristics, and 79.9 percent of participants in each group were boys.

Compared with controls, children with ASD had greater susceptibility to genetic syndrome, preterm birth, neonatal epilepsy, birth asphyxia and low birth weight. Furthermore, mothers of children with ASD were more likely to have gestational diabetes and younger age at delivery.

A total of 1,063 children had CHD: 401 in the ASD group and 662 in the control group. In multivariable conditional logistic regression models, any CHD was associated with about 30-percent increased odds of having ASD (odds ratio [OR], 1.33, 95 percent confidence interval [CI], 1.16–1.52).

The elevated ASD risk in CHD patients was largely driven by a significant risk increase observed in subgroups of patients with atrial septal defects (OR, 1.97, 95 percent CI, 1.48–2.61), ventricular septal defects (OR, 1.28, 95 percent CI, 1.00–1.63) and left heart obstructive lesions (OR, 1.42, 95 percent CI, 1.04–1.93).

Sensitivity analysis confirmed the relationship between CHD and increased ASD risk among patients with any CHD (OR, 1.32, 95 percent CI, 1.10–1.59), atrial septal defects (OR, 1.72, 95 percent CI, 1.07–2.74) and ventricular septal defects (OR, 1.65, 95 percent CI, 1.21–2.25).

The present data may be used for counselling parents of children with CHD, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.